FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212
Merck Sharp x26 Dohme Corp Institute De Recherche Pierre Fabre

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors


Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015008650503/26/15Mono- and di-peg il-10 production; and uses
22015001159001/08/15Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
32012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
42012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
52015011939404/30/15 new patent  Insulin-like growth factor-1 receptor inhibitors
62015011186604/23/15Cyclic amine substituted heterocyclic cetp inhibitors
72015011187704/23/15Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
82015011191404/23/15Spirolactam cgrp receptor antagonists
92015010445304/16/15Fdf03 antibodies and uses thereof
102015010446504/16/15Il-19 as a biomarker of tslp treatment
112015010531704/16/15Glucose-responsive insulin conjugates
122015010535404/16/15Heterocyclic aspartyl protease inhibitors
132015009989104/09/15Novel crystalline forms of a dipeptidyl peptidase-iv inhibitors
142015009971504/09/15Formulations of acadesine
152015009971904/09/15Cathepsin cysteine protease inhibitors
162015009972904/09/15Inhibitors of the renal outer medullary potassium channel
172015009977104/09/15Pyridine cgrp receptor antagonists
182015009339804/02/15Methods and compositions for treating or preventing cancer
192015008390603/26/15Biomarkers for monitoring intervention therapies for diabetes
202015008764103/26/15Heterocyclic cgrp receptor antagonists
212015008783203/26/15Process for making beta 3 agonists and intermediates
222015007899603/19/15Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
232015007903103/19/15Use of pegylated il-10 to treat cancer
242015008059803/19/15Asymmetric synthesis for preparing fluoroleucine alkyl esters
252015006419203/05/15Mammalian cell surface antigens; related reagents
262015005619102/26/15Igf1 biomarker for igf1r inhibitor therapy
272015005122702/19/15Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
282015005124802/19/15Imidazolyl methyl piperidine t-type calcium channel antagonists
292015004425002/12/15Vaccines against clostridium difficile comprising recombinant toxins
302015004534602/12/15Selective glycosidase inhibitors and uses thereof
312015004557502/12/15Process for preparing fluoroleucine alkyl esters
322015003849002/05/15Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
332015003849802/05/15Thrombin inhibitors
342015003850202/05/15Isoxazolopyridine orexin receptor antagonists
352015003870702/05/15Process for making cgrp receptor antagonists
362015003171301/29/15Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
372015003171601/29/15Piperidinone carboxamide azaindane cgrp receptor antagonists
382015003189101/29/15Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
392015002080601/22/15Dry powder inhaler for delivering multipe agglomerate formulations
402015002395201/22/15Anti-addl monoclonal antibody and uses thereof
412015002407101/22/15Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
422015002504601/22/15Preparation and use of bicyclic himbacine derivatives as par-1 receptor antagonists
432015001768601/15/15Methods for reducing mannosyltransferase activity in lower eukaryotes
442015001839901/15/15Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
452015001056401/08/15Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
462015000460801/01/15Monocyte-derived nucleic acids and related compositions and methods
472015000533001/01/15Piperidinone carboxamide azaindane cgrp receptor antagonists
482014037726012/25/14Protective vaccine based on staphylococcus aureus sa2074 protein
492014037849312/25/14Fused bicyclic oxazolidinone cetp inhibitor
502014037002512/18/14Uses of mammalian cytokines and agonists; related reagents
512014037113812/18/14Inhibitors of hepatitis c virus replication
522014034997211/27/14Substituted pyrimidines
532014034884111/27/14Anti-gitr antibodies
542014034999811/27/14Pyrrolopyrimidines as janus kinase inhiitors
552014035000211/27/14Imidazopyridin-2-one derivatives
562014034307111/20/14Compositions and methods for treating cancer
572014033619611/13/14Phosphoric acid salts of sitagliptin
582014032927611/06/14Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
592014032351910/30/14Heterocyclic compounds as b-raf inhibitors for treatment of cancer
602014029620210/02/14Substituted piperidinyl compounds useful as gpr119 agonists
612014029622110/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
622014029622210/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
632014027501709/18/14Cgrp receptor antagonists
642014025681809/11/14Nano-suspension process
652014024428908/28/14Cold storage system for storing pharmaceutical product containers
662014023429608/21/14Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
672014023430108/21/14Modulation of pilr to treat immune disorders
682014023553708/21/14N-glycosylated insulin analogues
692014022562708/14/14Device for calibrating and verifying the integrity of resistivity-based sensing probes
702014022722308/14/14Pegylated interleukin-10
712014022725008/14/14Stable formulations of antibodies to tslp
722014022729008/14/14Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
732014022729208/14/14Anti-mcam antibodies and associated methods of use
742014022002708/07/141d05 pcsk9 antagonists
752014022138308/07/14Cetp inhibitors
762014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
772014020656307/24/14Biomarkers for psoriasis
782014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
792014020664107/24/14Remedy
802014020666507/24/14Selective glycosidase inhibitors and uses thereof
812014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
822014020671507/24/14Preparation and use of compounds as protease inhibitors
832014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
842014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
852014017015406/19/14Engineered anti-il-23r antibodies
862014017065806/19/14Mammalian cytokines; related reagents
872014017143706/19/14Oxazole derivatives useful as inhibitors of faah
882014017145606/19/14Fused tricyclic compounds as mtor inhibitors
892014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
902014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
912014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
922014014744205/29/14Use of il-23 antagonists for treatment of infection
932014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
942014014095405/22/14Methods of modulating cytokine activity; related reagents
952014014101205/22/14Engineered anti-tslp antibody
962014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
972014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
982014014211505/22/14Inhibitors of the renal outer medullary potassium channel
992014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
1002014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
1012014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
1022014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
1032014011291904/24/14Interleukin-10 antibodies
1042014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1052014010588704/17/14Methods for modulating il-33 activity
1062014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
1072014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
1082014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
1092014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
1102014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
1112014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
1122014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
1132014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1142014004574602/13/14Antidiabetic tricyclic compounds
1152014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
1162014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
1172014003762702/06/14Modulation of pilr receptors to treat microbial infections
1182014003894202/06/14Rorgammat inhibitors
1192014003897002/06/14Bridged and fused antidiabetic compounds
1202014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
1212014003076001/30/14Pavec
1222014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
1232014003134901/30/14Inhibitors of the renal outer medullary potassium channel
1242014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
1252014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1262013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
1272013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
1282013032323912/05/13Modulation of pilr receptors to treat sepsis
1292013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
1302013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
1312013032448312/05/13Mammalian cell surface antigens; related reagents
1322013032461012/05/13Cathepsin cysteine protease inhibitors
1332013032472812/05/13Process for the preparation of an orexin receptor antagonist
1342013031635411/28/13Mammalian cytokine; related reagents
1352013029627811/07/13Diazeniumdiolate derivatives
1362013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
1372013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
1382013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
1392013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1402013025167709/26/13Genetic markers associated with interferon-alpha response
1412013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
1422013023751809/12/13Novel compounds that are erk inhibitors
1432013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
1442013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1452013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1462013021657508/22/13Recombinant subunit dengue virus vaccine
1472013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1482013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1492013021776608/22/13Formulations for cathepsin k inhibitors
1502013020306008/08/13Mammalian genes; related reagents
1512013018927807/25/13Antagonists of pcsk9
1522013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1532013015672906/20/13Mammalian receptor proteins; related reagents and methods
1542013015677106/20/13Fdf03 antibodies and uses thereof
1552013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1562013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1572013013104105/23/13Spirocyclic compounds
1582013013104205/23/13Spiroxazolidinone compounds
1592013012200905/16/13Engineered anti-il-23p19 antibodies
1602013012320005/16/13Mammalian cell surface antigens; related reagents
1612013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1622013011522305/09/13Antagonists of pcsk9
1632013011623105/09/13Tyrosine kinase inhibitors
1642013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1652013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1662013007139003/21/13Method for preparing antibodies having improved properties
1672013006481703/14/13Engineered anti-il-23r antibodies
1682013005985003/07/13Aza-indole derivatives useful as modulators of faah
1692013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1702013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1712013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1722013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1732013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1742013003531202/07/13Cathepsin cysteine protease inhibiors
1752013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1762013001804801/17/13Oxazole derivatives useful as modulators of faah
1772013001252601/10/13Oxazole derivatives useful as modulators of faah
1782013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1792013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1802012032967912/27/12Eukaryotic cell display systems
1812012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1822012031620012/13/12Pyridone derivatives
1832012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1842012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1852012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1862012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1872012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1882012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1892012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1902012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1912012019690108/02/12Tertiary amide orexin receptor antagonists
1922012019070107/26/12Renin inhibitors
1932012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
1942012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
1952012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1962012016415806/28/12Anti-addl monoclonal antibody and use thereof
1972012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1982012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1992012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
2002012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
2012012014275206/07/12Hiv protease inhibitors
2022012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
2032012012162405/17/12Hepatitis c virus ns3 protease inhibitors
2042012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
2052012012150805/17/12Radiolabeled cgrp antagonists
2062012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
2072012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
2082012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
2092012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
2102012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
2112012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
2122012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
2132012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
2142012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2152012008348304/05/12Inhibitors of hepatitis c virus replication
2162012008267904/05/12Antagonists of pcsk9
2172012008268004/05/12Antagonists of pcsk9
2182012007679903/29/12Antagonists of pcsk9
2192012007796403/29/12Antagonists of pcsk9
2202012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
2212012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
2222012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
2232012003521402/09/12Renin inhibitors
2242012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
2252012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
2262012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
2272012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
2282012002107401/26/12P2x3, receptor antagonists for treatment of pain
2292012002194801/26/12Surface display of whole antibodies in eukaryotes
2302012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
2312012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
2322012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
2332012000958001/12/12Methods for quantitating small rna molecules
2342012001019301/12/12Cgrp receptor antagonists
2352012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
2362012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
2372012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
2382012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
2392011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2402011030107912/08/11Neuromedin u receptor agonists and uses thereof
2412011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules
2422011029473512/01/11Mechanism of neuromedin u action and uses thereof
2432011029477712/01/11Beta-lactamase inhibitors
2442011026353310/27/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2452011025059110/13/11Method of designing sirnas for gene silencing
2462011025120710/13/11Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
2472011024051110/06/11Packaging for oxygen-sensitive pharmaceutical products
2482011023763409/29/11Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
2492011022950809/22/11Polypeptides for inducing a protective immune response against staphylococcus aureus



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE